Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data.

Abstract

Investigate the clinical landscape of ovarian carcinoma (OC) over time. Register-based prospectively collected data. South East Scotland. A total of 2805 OC patients diagnosed in 1981-2015. Survival times were visualised using the Kaplan-Meier method; median survival, 5-year survival probabilities and associated restricted mean survival time analyses were used to quantify survival differences. Disease-specific survival. A significant increase in disease-specific survival (DSS) from 1981-1985 to 2011-2015 was observed (median 1.73 versus 4.23years, P<0.0001). Corresponding increase in progression-free survival (PFS) was not statistically significant (median 1.22 versus 1.58years, P=0.2568). An increase in the proportion of cases with low residual disease volume (RD) (<2cm RD) following debulking was observed (54.0% versus 87.7%, P<0.0001). The proportion of high grade serous (HGS) cases increased (P<0.0001), whereas endometrioid and mucinous cases decreased (P=0.0005 and P=0.0002). Increases in stage IV HGS OCincidence (P=0.0009) and stage IV HGSOC DSS (P=0.0122) were observed. Increasing median age at diagnosis correlated with increasing Eastern Cooperative Oncology Group Performance Status (ECOG PS) over time (r=0.86). OC DSS has improved over the last 35years. PFS has not significantly increased, highlighting that improvement in outcome has been limited to extending post-relapse survival. Distribution of stage at diagnosis, histological subtype and RD following debulking has changed over time, reflecting evolution in tumour classification, staging and optimal debulking definitions (from low RD to minimal or zero RD). Histology, stage, RD and ECOG PS remain reliable outcome predictors. Increasing median age at diagnosis and ECOG PS indicates demographic shifts in the clinical population. Significant improvement in ovarian carcinoma survival has been seen over time. Most of this improvement is due to an extension of survival following disease relapse.